Ace Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser restores the eye’s natural dynamic range of focus through Laser Scleral Microporation (LSM), allowing patients to see clearly at all distances with the eye’s natural functionality. The VisioLite® Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.
Explore More Articles
VIDEO: Innovations in Presbyopia Management: Laser Scleral Microporation
A novel procedure-based treatment for presbyopia, called laser scleral microportion (LSM), aims to restore dynamic range of focus by un-crosslinking the sclera. Mitchell A. Jackson, MD, joins host I. Paul Singh, MD, to talk about the procedure and 24-month outcomes from a recently presented study.
read moreMicroporation may address aging in eye
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, AnnMarie Hipsley, DPT, PhD, discusses microporation therapeutics and its potential role in presbyopia treatment.
read moreLaser scleral microporation aids near vision without compromising distance vision
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses results of laser scleral microporation in patients with presbyopia.
read more